Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.
2 reports, 1 independent
Updated Sep 1
No new developments lately
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Hutchison MediPharma and AstraZeneca are jointly developing savolitinib TKI, with clinical data presentations scheduled for WCLC 2025 and CSCO Annual Meeting 2025.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Major pharmaceutical companies, including BioNTech, DUALITY, Roche, and AstraZeneca, are competing in the Antibody-Drug Conjugate (ADC) market for breast cancer treatments.Also in this story
- Astex Pharmaceuticals and Newcastle University formed a strategic alliance with Hoffmann-La Roche to license breast cancer compounds.
- Pfizer and Genmab are collaborating on TIVDAK, which combines Genmab's antibody with Pfizer's ADC technology.
- ADC Therapeutics received accelerated approval for its drug from the FDA.
The entities involved
-
Hutchison MediPharma Limited
biopharmaceutical company
Nothing else this week.
-
AstraZeneca
British-Swedish pharmaceutical company
Coverage
Newest first; wire copies grouped- GlobeNewswireHUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025 HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEW